Table 1.
Patient characteristics and clinical outcomes.
| Characteristics | Total (n = 129), n (%) | 5Y OS (%) | p-Value |
|---|---|---|---|
| Age, years | |||
| <40 | 46 (35.7) | 80.4 | 0.74 |
| 40–50 | 56 (43.5) | 73.2 | |
| ≥50 | 27 (21) | 74.1 | |
| Menopausal status | |||
| Postmenopausal | 23 (17.9) | 69.6 | 0.453 |
| Perimenopausal | 3 (2.4) | 100 | |
| Premenopausal | 102 (79.1) | 76.5 | |
| Unknown | 1 (0.8) | ||
| Clinical Stage | |||
| II | 14 (10.9) | 100 | 0.037 |
| III | 115 (89.2) | 73.0 | |
| Clinical T stage | |||
| 1 | 2 (1.6) | 100 | 0.669 |
| 2 | 52 (40.4) | 82.7 | |
| 3 | 59 (45.8) | 69.5 | |
| 4 | 16 (12.5) | 75 | |
| Clinical N stage | |||
| 0 | 6 (4.7) | 100 | 0.39 |
| 1 | 18 (14) | 72.2 | |
| 2 | 70 (54.3) | 78.6 | |
| 3 | 35 (27.2) | 68.6 | |
| Molecular subtype | |||
| HR+, HER2− | 61 (47.3) | 83.6 | <0.001 |
| HR+, HER2+ | 22 (17.1) | 95.5 | |
| HR−, HER2+ | 17 (13.2) | 70.6 | |
| TN (HR−, HER2−) | 29 (22.5) | 48.3 | |
| Pathologic Stage (AJCC 7th) | |||
| 0 | 10 (7.8) | 90 | 0.378 |
| I | 26 (20.2) | 84.6 | |
| II | 42 (32.6) | 76.2 | |
| III | 51 (39.6) | 68.6 | |
| Nuclear grade (NG) | |||
| 1 | 18 (14) | 88.9 | 0.071 |
| 2 | 40 (31.1) | 85.0 | |
| 3 | 70 (54.3) | 68.6 | |
| Unknown | 1 (0.8) | ||
| Histologic grade (HG) | |||
| 1 | 25 (19.4) | 96 | <0.001 |
| 2 | 61 (47.3) | 80.3 | |
| 3 | 31 (24.1) | 48.4 | |
| Unknown | 12 (9.4) | ||
| Ki-67 score | |||
| ≤20% | 63 (48.9) | 88.9 | <0.001 |
| 20%< | 58 (45) | 58.6 | |
| Unknown | 8 (6.3) |
Overall survival (OS) was determined by Kaplan–Meier analysis and the log-rank test. p-values ≤ 0.05 were considered significant.